NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.
Financial Results:
Natco Pharma Ltd reported Revenues for Q2FY25 of ₹1,371.00 Crores up from ₹1,031.00 Crore year on year, a rise of 32.98%.
Total Expenses for Q2FY25 of ₹617.00 Crores down from ₹621.00 Crores year on year, a fall of 0.64%.
Consolidated Net Profit of ₹676.00 Crores up 83.2% from ₹369.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹37.81, up 83.54% from ₹20.60 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.